阻塞性睡眠呼吸暂停治疗、慢波活动与β-淀粉样蛋白
本研究在阻塞性睡眠呼吸暂停(OSA)患者中,于治疗前和治疗后1至4个月测量慢波活动(SWA)和脑脊液β-淀粉样蛋白(Aβ)。OSA治疗增加了SWA,治疗后SWA与较低的Aβ显著相关,且OSA改善程度越大Aβ下降越多。提出OSA治疗可能影响Aβ释放和清除的模型。
要点
- OSA治疗可增加慢波活动(SWA)。
- 治疗后SWA与较低脑脊液Aβ显著相关。
- OSA改善越大,Aβ下降越多。
核心结论
- OSA治疗可能通过影响Aβ释放和清除来降低Aβ水平。
研究设计与样本
- 在OSA患者中,于治疗前和治疗后1至4个月测量SWA和脑脊液Aβ。
主要发现
- OSA治疗增加了SWA。
- 治疗后SWA与较低的Aβ显著相关。
- OSA改善程度越大,Aβ下降越多。
临床怎么用
- 对OSA患者进行有效治疗可能有助于改善慢波活动并降低Aβ水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obstructive sleep apnea (OSA) increases risk of dementia, a relationship that may be mediated by amyloid-β (Aβ) and downstream Alzheimer disease pathology. We previously showed that OSA may impair Aβ clearance and affect the relationship between slow wave activity (SWA) and Aβ. In this study, SWA and CSF Aβ were measured in participants with OSA before and 1 to 4 months after treatment. OSA treatment increased SWA, and SWA was significantly correlated with lower Aβ after treatment. Greater improvement in OSA was associated with greater decreases in Aβ. We propose a model whereby OSA treatment may affect both Aβ release and clearance. Ann Neurol 2018 ANN NEUROL 2019;85:291-295.
引用
- Ju YS, Zangrilli MA, Finn MB, et al. Obstructive sleep apnea treatment, slow wave activity, and amyloid-β. Ann Neurol. 2019. PMID: 30597615. doi:10.1002/ana.25408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。